The human receptor for the complement cleavage fragments C3b and C4b (complement receptor type 1, CRl) is found on the surfaces of erythrocytes, most peripheral blood leukocytes, glomerular podocytes, and follicular dendritic cells, and in plasma (1-3). Besides the removal of C3b-or C4b-coated microorganisms or immune complexes (4), CRl also serves as an inhibitor of the C3 and the C5 convertases by dissociating C2b and Bb fragments and by acting as a cofactor for the factor I-mediated cleavage of C3b and C4b (5, 6) . This regulatory capacity is shared by the structurally related members of a supergene family, termed the regulator of complement activation (RCA)t region, located on chromosome 1 (7-13) .Human CRl is a single chain glycoprotein with four allotypic variants that differ in Mr on SDS-PAGE by increments of 40-50 kD (14-17). The two most common variants are termed F and S (or A and B allotypes) and exhibit Mr of 250 and 290 kD, respectively. These variations reflect differing lengths of the polypeptides and not posttranslational modifications, since distinct unglycosylated precursors have been described (18) and incremental differences of 1.3 to 1.5 kb were also observed in the CRl transcripts from various allotypes (19,20). The cDNA that encodes the entire F allotype of 2,039 amino acids (aa) has been sequenced and the extracellular portion of the molecule is found to comprise 30 short consensus repeats (SCR). A feature that distinguishes CR1 from the other proteins of this gene family is the organization of the NH2-terminal 28 SCRs into four tandem long homologous repeats (LHR) of about 450 aa, each containing seven SCRs . Extensive sequence homologies of 60 to 99% have been observed among the LHRs, suggesting that they have arisen by gene duplication (21,22).
Human CR1 exhibits an unusual form of polymorphism in which allotypic variants differ in the molecular weight of their respective polypeptide chains. To address mechanisms involved in the generation of the CR1 allotypes, DNA from individuals having the F allotype (250,000 Mr), the S allotype (290,000 Mr), and the F' allotype (210,000 Mr) was digested by restriction enzymes, and Southern blots were hybridized with CR1 cDNA and genomic probes. With the use of Bam HI and Sac I, an additional restriction fragment was observed in 20 of 21 individuals having the S allotype with no associated loss of other restriction fragments. Southern blot analysis with a noncoding genomic probe derived from the S allotype-specific Bam HI fragment showed hybridization to this fragment and to two other fragments that were also present in FF individuals. Thus, an intervening sequence may be repeated twice in the F allele and three times in the S allele. A restriction fragment length polymorphism (RFLP) unique to two individuals expressing the F' allotype was seen with Eco RV, but the absence of persons homozygous for this rare allotype prevented further comparisons with the F and S allotypes. Analysis of the CR1 transcripts associated with the three CR1 allotypes indicated that these differed by 1.3-1.5 kb and had the same rank order as the corresponding allotypes. Taken together, these findings suggest that the S allele was generated from the F allele by the acquisition of additional sequences, the coding portion of which may correspond to a long homologous repeat of approximately 1.4 kb that has been identified in CR1 cDNA. We saw two other RFLPs with Hind III and Pvu II that were in linkage dysequilibrium with the Bam HI-Sac I RFLPs associated with the S allotype, and a third polymorphism was seen with Eco RI that was not in linkage dysequilibrium with the other polymorphisms. Thus, 10 commonly occurring CR1 alleles can be defined, making this locus a useful marker for the long arm of chromosome 1 to which the CR1 gene maps.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.